Aileron raises $30m to advance second stapled peptide
This article was originally published in Scrip
Executive Summary
Aileron Therapeutics will use $30m from a Series E venture funding round to take its second stapled peptide into the clinic after the Cambridge, Massachusetts-based company collected its first set of clinical data from another therapeutic candidate earlier this year.